LENZ Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024
Rhea-AI Summary
LENZ Therapeutics (Nasdaq: LENZ), a late clinical-stage biopharmaceutical company, has announced it will report its second quarter 2024 financial results on August 14, 2024. The company, which is developing the first aceclidine-based eye drop for presbyopia, will host a webcast at 4:30 p.m. ET to present the results and provide a business update. Investors and interested parties can access the live webcast through the company's website, where a replay will be available for 30 days following the event.
Positive
- LENZ is in the late clinical-stage of developing a novel treatment for presbyopia
- The company is publicly traded on Nasdaq, indicating a certain level of financial stability and investor interest
Negative
- None.
News Market Reaction
On the day this news was published, LENZ gained 4.01%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye to improve near vision in people with presbyopia, today announced it will host a webcast on Wednesday, August 14, 2024 at 4:30 p.m. ET to report its second quarter 2024 financial results and provide a business update.
The live webcast can be accessed here and on the LENZ Therapeutics website at www.LENZ-tx.com in the Investors & Media section. A replay of the webcast will be available on the Company’s website for 30 days following the event.
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on the development and commercialization of the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidate, LNZ100 is a preservative-free, single-use, once-daily eye drops containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase 3 CLARITY trials as a potential therapy for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is committed to commercializing an ideal pharmaceutical presbyopia solution that enhances vision for “all eyes, all day.” LENZ is headquartered in San Diego, California. For more information, visit: LENZ-Tx.com.
Contacts:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com
FAQ
When will LENZ Therapeutics report its Q2 2024 financial results?
What is LENZ Therapeutics developing?
How can investors access LENZ Therapeutics' Q2 2024 financial results webcast?
What is LENZ Therapeutics' stock symbol?
